Skip to main content

Table 1 Comparison of TRIM9 methylation ratio with various clinicopathological parameters of breast tumors

From: Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients

Characteristics Total TRIM9
Methylation ratio mean ± SE P value*
All cases 107   
 Age (years)
  <50 49 11.2 ± 1.54 0.052
  ≥50 58 7.44 ± 1.10  
 Menopausal status
  Pre 51 10.7 ± 1.51 0.117
  Post 56 7.73 ± 1.14  
 Tumor size
  T1+2 84 8.97 ± 1.04 0.709
  T3+4 23 9.83 ± 2.19  
 Lymph node metastasis
  Negative 30 10.9 ± 2.27 0.338
  Positive 77 8.48 ± 0.96  
 Stage
  II 88 9.02 ± 1.02 0.768
  III 19 9.75 ± 2.50  
 Histological type
  IDC 97 8.66 ± 0.99 0.104
  ILC 10 13.9 ± 2.68  
 Estrogen receptor
  Negative 42 3.47 ± 0.56 <0.0001
  Positive 65 12.8 ± 1.32  
 Progesterone receptor
  Negative 65 6.93 ± 1.01 0.005
  Positive 42 12.6 ± 1.70  
 HER2 receptor
  Negative 76 9.07 ± 1.10 0.893
  Positive 31 9.35 ± 1.85  
 TNBC
  No 82 11.2 ± 1.13 <0.0001
  Yes 25 2.39 ± 0.32  
 Subtype (IHC)
  LumA 51 12.3 ± 1.42 <0.0001
  LumB 14 14.6 ± 3.40  
  HER2 17 5.06 ± 1.21  
  TN 25 2.39 ± 0.32  
 Subtype (PAM50)
  LumA 29 13.7 ± 1.89 <0.0001
  LumB 21 10.1 ± 2.24  
  HER2 16 9.90 ± 2.65  
  Basal-like 23 3.22 ± 0.84  
  Normal-like 18 7.70 ± 2.24  
 Histological grade
  1+2 86 9.89 ± 1.09 0.112
  3 21 6.12 ± 1.64  
 Ki67
  Low (<20 %) 44 10.2 ± 1.31 0.366
  High (≥20 %) 62 8.43 ± 1.33  
  Unknown 1   
 Clinical response
  No CR 70 8.62 ± 1.13 0.434
  CR 37 10.2 ± 1.70  
 Histological response
  Grade 1, 2a 58 11.4 ± 1.37 0.006
  Grade 2b, 3 49 6.45 ± 1.17  
 Pathological response
  No pCR 74 11.0 ± 1.20 0.001
  Pcr 33 5.02 ± 1.15  
 Recurrence
  No 90 9.88 ± 1.08 0.007
  Yes 17 5.30 ± 1.12  
  1. * t test